April 24-25, 2019
Representative: Meinolf Thiemann, Ph.D., Director Assay Development
Presentation on April 24 at 2:50 pm: "HERA-CD40L - A Novel Co-Stimulatory Agonist"
May 6-9, 2019
Representative: Ulrike Jaegle, Ph.D., VP Regulatory Affairs
May 15-17, 2019
Representative: Christian Merz, Ph.D., Head of Cellular Analytics
Presentation on May 16 at 4:20 pm: "The tHERApeutic potential of HERA-CD40L in immunologic cancer treatment"
May 20-21, 2019
Representative: Katharina Billian-Frey, Ph.D., Senior Scientist Drug Discovery/Protein Engineering
Presentation on May 21 at 2:30 pm: "HERA-CD40L: A Unique Hexavalent CD40 Agonist for Cancer Immunotherapy"
May 21-23, 2019
Niclas Kneisel, Ph.D., Alliance Manager
David Richards, Ph.D., Head of Immunology
Matthias Schroeder, Ph.D., Senior Scientist Assay Development
Julian Sefrin, Ph.D., Senior Scientist Immunology
"HERA-CD40L, a hexavalent CD40 agonist, induces a significant T cell mediated anti-tumor immune response and shows superior activity in direct comparison to benchmark agonistic antibodies"
Poster Presentation: May 22, 3:30-6:00 pm; Oral Talk: May 23, 10:30-11:45 am ("Improving Immunity" session) - David Richards
"The novel hexavalent human GITR agonist HERA-GITRL promotes anti-tumor efficacy independent of Fc-functionality and shows superior activity compared with the monoclonal anti-GITR antibody TRX518"
Poster Presentation: May 22, 3:30-6:00 pm ("Tumor Biology and Interaction with the Immune System" session) - Matthias Schroeder
"HERA-CD27L, a true CD27 agonist, has superior activity over benchmark agonistic antibodies and induces T cell activation for potent anti-tumor immunity"
Poster Presentation: May 22, 3:30-6:00 pm ("New Targets & New Leads" session) - Julian Sefrin
May 31 - June 4, 2019
Chicago, IL, USA
Representative: Andriy Krendyukov, M.D., MBA, VP Medical Affairs